# Jiangsu Aosaikang Pharmaceutical Co., Ltd.: Phase 3 study in EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (425 participants)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Jiangsu Aosaikang Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC |
| NCT ID | NCT07897188 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | EGFR Activating Mutation; Non-Squamous Non-Small Cell Lung Cancer (NSCLC); MET Positive |
| Intervention types | drug |
| Target enrollment | 425 |
| Site countries | China |
| Posted | 2026-10-27 |
| Planned start | 2026-10-30 |
| Event | Newly registered study |
| Event date | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 425 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07897188). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.